| DC45318 |
Aurora kinase inhibitor-2
|
Aurora kinase inhibitor-2 is a selective and ATP-competitive Aurora kinase inhibitor with IC50s of 310 nM and 240 nM for Aurora A and Aurora B, respectively. |
| DC44124 |
TAS-119
|
TAS-119 is a potent, selective and orally active Aurora A inhibitor with an IC50 of 1.0 nM. TAS-119 shows high selectivity for Aurora A over other protein kinases, including Aurora B (IC50 of 95 nM). TAS-119 has potent antitumor activites. |
| DC39107 |
SP-146
|
SP-146 is a potent, selective and non-ATP-competitive inhibitor of Aurora B with IC50 of 0.316 nM. SP-146 can be used for the research of triple negative breast cancer (TNBC). |
| DC1084 |
ZM447439 (ZM-447439)
|
ZM-447439 is a selective and ATP-competitive inhibitor for Aurora A and Aurora B with IC50 of 110 nM and 130 nM, respectively. |
| DC5111 |
PHA-680632
|
PHA-680632 is potent inhibitor of Aurora A, Aurora B and Aurora C with IC50 of 27 nM, 135 nM and 120 nM, respectively. It has 10- to 200-fold higher IC50 for FGFR1, FLT3, LCK, PLK1, STLK2, and VEGFR2/3. |
| DC9365 |
MLN8054
|
MLN8054 is a potent and selective inhibitor of Aurora A with IC50 of 4 nM; exhibits more than 40-fold selective for Aurora A than Aurora B.
|
| DC7325 |
CYC116
|
CYC116 is a potent inhibitor of Aurora A/B with Ki of 8.0 nM/9.2 nM. |
| DC73156 |
LXY18
|
LXY18 is a potent orally available blocker of AURKB relocation in mitosis with minimum effective concentration (MEC) of 3.5 nM for inducing polyploidy, shows broad-spectrum growth inhibitory and apoptosis-inducing activities with low nanomolar potencies. |
| DC70400 |
F114
|
F114 is a novel, first-in-class, dual aurora and lim kinase inhibitor with IC50 of 72 nM and 137 nM against Aurora-A and Limk1, respectively, F114 inhibits GBM proliferation and invasion. |
| DC49552 |
dAURK-4 hydrochloride
|
dAURK-4 hydrochloride, an Alisertib derivative, is a potent and selective AURKA (Aurora A) degrader. dAURK-4 hydrochloride has anticancer effects. |
